Novartis's statement supports the ongoing trust and marketability of Kymriah, which could maintain or potentially increase investor confidence in the short term. The reaffirmation of the drug's benefit/risk profile suggests that there are no imminent regulatory challenges or negative market perceptions that could adversely affect the stock price.